Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04643366 · ClinicalTrials.gov registry record · Phase 2
Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer
A Phase 2 study of Rectal Cancer, sponsored by Virginia Commonwealth University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 3
- Study locations
NCT04643366: Recruiting Phase 2 study of Rectal Cancer, sponsored by Virginia Commonwealth University.
NCT04643366 is a Phase 2 study of Rectal Cancer that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 54 participants, below the 3,166-participant average among 70 other Rectal Cancer trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04643366, a Phase 2 study of Rectal Cancer, is actively recruiting participants, sponsored by Virginia Commonwealth University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is phase 2 trial of neoadjuvant therapy and short-course radiotherapy in resectable rectal cancer.
Primary Outcome
The three-year disease free survival (DFS) defined as the number of patients alive without recurrence of disease at 3 years measured from the date of clinical complete response (cCR) or date of total mesorectal excision (TME) at surgery (whichever is earlier).
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DRUG Chemotherapy
Study Locations (3)
Virginia
- Virginia Cancer Institute - Richmond
- Virginia Commonwealth University Massey Cancer Center - Richmond
- VCU Community Memorial Healthcenter - South Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2021-01-28 |
| Est. Completion | 2033-01-31 |
| Phase | Phase 2 |
What NCT04643366 shows while recruiting
NCT04643366 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 3,166-participant average among 70 other Rectal Cancer trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Rectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Radiation Therapy is the first listed.
NCT04643366 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT04643366 about?
NCT04643366 is a clinical study titled "Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer". This is phase 2 trial of neoadjuvant therapy and short-course radiotherapy in resectable rectal cancer.
What is the current status of trial NCT04643366?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2021-01-28. Estimated completion is 2033-01-31.
What conditions does trial NCT04643366 study?
This clinical trial studies the following conditions: Rectal Cancer.
What interventions are being tested in trial NCT04643366?
The interventions under investigation include: Radiation Therapy (RADIATION), Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT04643366?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04643366 being conducted?
This trial has 3 study locations across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04643366's enrollment target sits among peer trials
54 36th of 70 higher than 34 of 70 other Rectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
RECRUITING · Phase 2
-
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
RECRUITING · Phase 2
-
Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001
RECRUITING · Phase 2
-
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 2
-
Watchful Waiting for Complete Responders to Therapy in Rectal Cancer
RECRUITING · Phase 2
-
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy